2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial
Circulation: Arrhythmia and Electrophysiology · 2025-08 · 18 (8)
DOI: 10.1161/circep.124.013378 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2025-08. Verfasst von Zachary T Yoneda und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Anti-Arrhythmia Agents, Benzylamines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NCATS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Inflammation is a common mechanism for atrial fibrillation (AF). 2-Hydroxybenzylamine (2-HOBA) is a novel therapeutic that scavenges isolevuglandins—a downstream mediator of inflammation and oxidative stress. 2-HOBA is safe and reduces AF in mice, prompting a first-in-human pilot clinical trial. METHODS: Participants were enrolled and randomized 1:1 to placebo or 2-HOBA (750 mg p.o. TID) 3 days before a planned AF ablation. Participants were monitored for 28 days after their ablation for recurrence of AF as detected by smartwatch single-lead ECG recordings. Blood was collected at the time of ablation for measurement of isolevuglandin levels. The study drug was stopped at 28 days. A 12-month extended follow-up period was used to monitor for any residual effect of the study drug on AF recurrence. RESULTS: 2-HOBA increased the risk of AF recurrence in the postablation population (odds ratio, 3.65 [95% CI, 1.31–10.16]; P =0.013) after prespecified adjustment for potential confounders. This increased risk of recurrence remained despite post hoc adjustment for other clinical risk factors. There was no difference in isolevuglandin levels between the 2-HOBA and placebo groups. After the study drug was stopped, there was no difference in AF recurrence between the 2-HOBA and placebo groups during the 12-month extended follow-up. CONCLUSIONS: 2-HOBA was associated with a higher risk of AF recurrence when tested early after AF ablation. This result was unexpected based on preclinical data, but paradoxical associations with AF have been previously reported for other drugs that target inflammation and oxidative stress pathways, such as omega-3 fatty acids. The mechanisms for AF immediately following ablation may be different from AF that occurs under other conditions, and the generalizability of these results to all forms of AF remains unknown.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.
- Vanderbilt University School of Medicine, Nashville, TN (M.O.N.).
- Department of Pharmacology (M.A.), Vanderbilt University Medical Center, Nashville, TN.
- Department of Biostatistics (L.S., F.Y.), Vanderbilt University Medical Center, Nashville, TN.
- MTI Biotech, Inc, Iowa State University Research Park, Ames (L.P., J.A.R.).
- Department of Pharmaceutical Science, Lipscomb University, Nashville, TN (W.S.A.).
ORCID-Profile: Zachary T Yoneda, Diane M Crawford, Lili Sun, Lisa Pitchford, John A Rathmacher, Jay Montgomery, Sharon T Shen, Juan Carlos Estrada, Pablo J Saavedra, Christopher R Ellis, Travis Richardson, Arvindh Kangasundram, George H Crossley, Wendall S Akers, Fei Ye, Dan M Roden, Gregory F Michaud, M Benjamin Shoemaker
Förderung
- American Heart Association-American Stroke Association
- NCATS NIH HHS
Zitieren
APA
Yoneda, Z. T., O'Neill, M., Crawford, D. M., Ao, M., Sun, L., El-Harasis, M. A., Pitchford, L., Rathmacher, J. A., Montgomery, J., Shen, S. T., Estrada, J. C., Saavedra, P. J., Ellis, C. R., Richardson, T., Kangasundram, A., Crossley, G. H., Akers, W. S., Ye, F., Roden, D. M., …, & Shoemaker, M. B. (2025). 2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial. Circulation: Arrhythmia and Electrophysiology, 18(8). https://doi.org/10.1161/circep.124.013378
Vancouver
Yoneda ZT, O'Neill M, Crawford DM, Ao M, Sun L, El-Harasis MA, et al. 2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial. Circulation: Arrhythmia and Electrophysiology. 2025;18(8). doi:10.1161/circep.124.013378
BibTeX
@article{Yoneda2025,
author = {Yoneda, Zachary T and O'Neill, Matthew and Crawford, Diane M and Ao, Mingfang and Sun, Lili and El-Harasis, Majd A and Pitchford, Lisa and Rathmacher, John A and Montgomery, Jay and Shen, Sharon T and Estrada, Juan Carlos and Saavedra, Pablo J and Ellis, Christopher R and Richardson, Travis and Kangasundram, Arvindh and Crossley, George H and Akers, Wendall S and Ye, Fei and Roden, Dan M and Michaud, Gregory F and Shoemaker, M Benjamin},
title = {2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial},
journal = {Circulation: Arrhythmia and Electrophysiology},
year = {2025},
volume = {18},
number = {8},
doi = {10.1161/circep.124.013378}
}
EUVIMED